JPH11512297A - 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるdna構築物 - Google Patents
免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるdna構築物Info
- Publication number
- JPH11512297A JPH11512297A JP9512813A JP51281397A JPH11512297A JP H11512297 A JPH11512297 A JP H11512297A JP 9512813 A JP9512813 A JP 9512813A JP 51281397 A JP51281397 A JP 51281397A JP H11512297 A JPH11512297 A JP H11512297A
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- dna
- dna construct
- vector
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 筋肉特異的調節要素および該要素に操作可能に連結されたDNA配列か らなるDNA構築物。 2.筋肉特異的調節要素がプロモーターおよび少なくとも1つのエンハンサー からなる請求項1記載のDNA構築物。 3. 筋肉特異的調節要素がクレアチンキナーゼの筋肉イソ酵素(MCK)、 ミオシンLキナーゼ、筋肉特異的アルドラーゼ、筋肉特異的エノラーゼ、トロポ ニンC、およびミオシンからなる群から選択された遺伝子の調節要素である請求 項2記載のDNA構築物。 4. 筋肉特異的調節要素が配列番号2に記載するMCKのプロモーターおよ びエンハンサーである請求項2記載のDNA構築物。 5. DNA配列が抗原をコードしている請求項1記載のDNA構築物。 6. 抗原がウイルス性または細菌性肝炎、インフルエンザ、ジフテリア、破 傷風、百日咳、麻疹、流行性耳下腺炎、風疹、ポリオ、肺炎球菌、庖疹、RSウ イルス、ヘモフィルス・インフルエンザB型、クラミジア、水痘一帯状病疹ウイ ルスまたは狂犬病からなる群から選択される請求項5記載のDNA構築物。 7. DNA配列がアンチセンスRNAをコードしている請求項1記載のDN A構築物。 8. DNA配列が循環タンパク質をコードしている請求項1記載のDNA構 築物。 9. 循環タンパク質がインスリン、ペプチドホルモン、ヘモグロビン、成長 因子、肝臓酵素、凝固因子および酵素、補体因子、サイトカイン、組織壊死因子 ならびにエリトロポイエチンからなる群から選択される請求項8記載のDNA構 築物。 10. DNA配列が生物学的に機能的な分子タンパク質をコードしている請 求項1記載のDNA構築物。 11. 請求項1記載のDNA構築物を含有してなるベクター。 12. 宿主染色体中への組込みが可能なヌクレオチド配列をさらに含有して なる請求項11記載のベクター。 13. 宿主において複製可能なヌクレオチド配列をさらに含有してなる請求 項11記載のベクター。 14. 請求項2記載のDNA構築物を含有してなるベクター。 15. 宿主染色体中に組込みが可能なヌクレオチド配列をさらに含有してな る請求項14記載のベクター。 16. 宿主において複製可能なヌクレオチド配列をさらに含有してなる請求 項14記載のベクター。 17. 請求項5記載のDNA構築物および生理学的に許容される担体を含有 してなるベクター。 18. 請求項6記載のDNA構築物および生理学的に許容される担体を含有 してなるベクター。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/530,529 US5795872A (en) | 1995-09-19 | 1995-09-19 | DNA construct for immunization |
US08/530,529 | 1995-09-19 | ||
PCT/US1996/014829 WO1997011190A2 (en) | 1995-09-19 | 1996-09-19 | Dna construct comprising a muscle specific regulatory element for immunization or gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11512297A true JPH11512297A (ja) | 1999-10-26 |
Family
ID=24113962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9512813A Ceased JPH11512297A (ja) | 1995-09-19 | 1996-09-19 | 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるdna構築物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US5795872A (ja) |
EP (1) | EP0851935A2 (ja) |
JP (1) | JPH11512297A (ja) |
AU (1) | AU710756B2 (ja) |
CA (1) | CA2231806A1 (ja) |
WO (1) | WO1997011190A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019513389A (ja) * | 2016-04-15 | 2019-05-30 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するためのマイクロrna−29のアデノ随伴ウイルスベクター送達 |
WO2021107013A1 (ja) * | 2019-11-29 | 2021-06-03 | 国立研究開発法人理化学研究所 | アジュバント組成物 |
US11534501B2 (en) | 2017-10-18 | 2022-12-27 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060014710A9 (en) * | 1996-11-22 | 2006-01-19 | Adrian Bot | Immunization of infants |
US20020103145A1 (en) * | 1999-05-19 | 2002-08-01 | Adrian Bot | Immunization of infants |
US6391314B1 (en) * | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
JP4180238B2 (ja) | 1997-12-09 | 2008-11-12 | 株式会社コスモ総合研究所 | 環状フェノール硫化物のスルホン酸化合物及びその製造方法 |
WO2000025820A1 (en) * | 1998-11-04 | 2000-05-11 | Pharmadigm, Inc. | Compounds and methods for genetic immunization |
ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
DE10014690A1 (de) * | 2000-03-24 | 2001-10-18 | Franz Wolfgang M | Verfahren zur Isolierung in vito differenzierter Körperzellen |
AU2002305052A1 (en) | 2001-03-13 | 2002-09-24 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
JP2004535166A (ja) | 2001-03-22 | 2004-11-25 | デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー | セリンプロテアーゼcvsp14をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法 |
NZ527971A (en) | 2001-03-27 | 2006-03-31 | Dendreon Corp | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
WO2002092841A2 (en) | 2001-05-14 | 2002-11-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
EP1390490B1 (en) * | 2001-05-24 | 2009-04-15 | Genzyme Corporation | Muscle-specific expression vectors |
AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
EP1575500A4 (en) * | 2002-07-12 | 2007-01-03 | Univ Johns Hopkins | MESOTHELIN VACCINE AND MODEL SYSTEMS |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
EP1773858B1 (en) | 2004-05-27 | 2016-06-22 | Janssen Biotech, Inc. | Cynomolgus prostate specific antigen |
US20050276758A1 (en) * | 2004-06-15 | 2005-12-15 | Marshall Deborah J | Method for screening agents against human prostate disease |
GB201102091D0 (en) | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
GB201102090D0 (en) | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
WO2015048115A1 (en) | 2013-09-25 | 2015-04-02 | Zoetis Llc | Pcv2b divergent vaccine composition and methods of use |
US20160279207A1 (en) | 2015-03-10 | 2016-09-29 | University Of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
WO2023008881A1 (ko) * | 2021-07-29 | 2023-02-02 | 주식회사 에스엠엘바이오팜 | 발현 시스템 및 이를 포함하는 핵산 기반 약학 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169763A (en) * | 1986-04-08 | 1992-12-08 | Transgene S.A., Institut Pasteur | Viral vector coding glycoprotein of HIV-1 |
US5273876A (en) * | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
US5266488A (en) * | 1988-04-06 | 1993-11-30 | The Regents Of The University Of California | Troponin T gene promoter and derivatives thereof |
EP0351921A3 (en) * | 1988-07-22 | 1991-07-17 | Merck & Co. Inc. | Modified beta adrenergic receptor |
AU7174791A (en) * | 1990-01-26 | 1991-08-21 | Baylor College Of Medicine | Mutated promoter region from chicken skeletal alpha-actin gene |
US5352595A (en) * | 1991-09-03 | 1994-10-04 | Fred Hutchinson Cancer Research Center | Myod regulatory region |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
AU5896394A (en) * | 1992-11-10 | 1994-06-08 | Washington University | Pars planitis specific polypeptides |
ATE307212T1 (de) * | 1992-11-18 | 2005-11-15 | Arch Dev Corp | Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel |
GB9310441D0 (en) * | 1993-05-20 | 1993-07-07 | Royal Free Hosp School Med | Gene therapy |
-
1995
- 1995-09-19 US US08/530,529 patent/US5795872A/en not_active Expired - Fee Related
-
1996
- 1996-09-19 WO PCT/US1996/014829 patent/WO1997011190A2/en not_active Application Discontinuation
- 1996-09-19 AU AU71602/96A patent/AU710756B2/en not_active Ceased
- 1996-09-19 CA CA002231806A patent/CA2231806A1/en not_active Abandoned
- 1996-09-19 JP JP9512813A patent/JPH11512297A/ja not_active Ceased
- 1996-09-19 EP EP96933030A patent/EP0851935A2/en not_active Withdrawn
-
1998
- 1998-07-20 US US09/119,264 patent/US6310196B1/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019513389A (ja) * | 2016-04-15 | 2019-05-30 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するためのマイクロrna−29のアデノ随伴ウイルスベクター送達 |
US11298429B2 (en) | 2016-04-15 | 2022-04-12 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy |
US11406717B2 (en) | 2016-04-15 | 2022-08-09 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of microRNA-29 and micro-dystrophin to treat muscular dystrophy |
US11723986B2 (en) | 2016-04-15 | 2023-08-15 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy |
US11534501B2 (en) | 2017-10-18 | 2022-12-27 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
WO2021107013A1 (ja) * | 2019-11-29 | 2021-06-03 | 国立研究開発法人理化学研究所 | アジュバント組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP0851935A2 (en) | 1998-07-08 |
AU7160296A (en) | 1997-04-09 |
US5795872A (en) | 1998-08-18 |
US6310196B1 (en) | 2001-10-30 |
CA2231806A1 (en) | 1997-03-27 |
WO1997011190A3 (en) | 1997-06-26 |
WO1997011190A2 (en) | 1997-03-27 |
AU710756B2 (en) | 1999-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11512297A (ja) | 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるdna構築物 | |
WO1997011190A9 (en) | Dna construct comprising a muscle specific regulatory element for immunization or gene therapy | |
US5698202A (en) | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier | |
Bernards et al. | Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. | |
EP0259212B1 (fr) | Expression d'un antigène spécifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement préventif ou curatif de la tumeur correspondante | |
US6235523B1 (en) | Vectors for DNA immunization against cervical cancer | |
CA2673373C (en) | Rsv f-protein and its use | |
KR101745029B1 (ko) | 재조합 조류 파라믹소바이러스 백신 및 이의 제조 및 사용 방법 | |
IL174848A (en) | Nucleic acid construct and vaccine comprising the same for immunizing against a pathogen, allergy or cancer | |
KR20230050328A (ko) | Hbv에 대한 rna 레플리콘 백신 | |
WO2015181142A1 (en) | Cytomegalovirus complexes and uses thereof | |
EP1620558B1 (en) | Viral vectors expressing fusion of viral large envelope protein and protein of interest | |
TW202206598A (zh) | 對抗SARS-CoV-2之疫苗及其製品 | |
JP2000507229A (ja) | ヒト腫瘍遺伝子治療用組換えアデノウイルスベクター | |
WO2022161495A1 (en) | Recombinant sars-cov-2 vaccine | |
ES2310988T3 (es) | Particulas para terapia genica. | |
KR20230008707A (ko) | 코로나바이러스 치료용 백신 조성물 | |
CN116390749A (zh) | 使用嵌合cd40配体和冠状病毒疫苗增强免疫力 | |
JPH11504204A (ja) | 免疫回避タンパク質 | |
US20060286114A1 (en) | Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof | |
AU2004231119B2 (en) | Viral vectors expressing fusion of viral large envelope protein and protein of interest | |
CN117229371A (zh) | 新型冠状病毒变异毒株的S蛋白突变体及其基因工程化mRNA和疫苗组合物 | |
JP2002525109A (ja) | 組織発現を調節するための特異的ハイブリッドプロモーターの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060516 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060810 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060925 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070213 |